An A1-A1 mutant with improved binding and inhibition of beta 2GPI/antibody complexes in antiphospholipid syndrome
FEBS JOURNAL
Authors: Kolyada, Alexey; Karageorgos, Ioannis; Mahlawat, Pardeep; Beglova, Natalia
Abstract
beta 2 glycoprotein I (beta 2GPI) is the most common antigen for autoimmune antibodies in antiphospholipid syndrome (APS). Thrombosis is a clinical feature of APS. We created a molecule (A1-A1) that consists of two identical beta 2GPI-binding modules from ApoE receptor 2 (ApoER2). A1-A1 binds to beta 2GPI/antibody complexes, preventing their association with ApoER2 and anionic phospholipids, and reducing thrombus size in the mouse model of APS. Here, we describe a mutant of A1-A1 (mA1-A1ND) with improved affinity for beta 2GPI. mA1-A1ND inhibits the binding of beta 2GPI to cardiolipin in the presence of anti-beta 2GPI antibodies, and inhibits the binding to phospholipids in plasma samples of APS patients, affecting the clotting time. Reduction of the clotting time demonstrates the presence of soluble beta 2GPI/antibody complexes in patients' plasma. These complexes either already exist in patients' plasma or form rapidly in the proximity to phospholipids. All members of the low-density lipoprotein receptor family bind beta 2GPI. Modeling studies of A1 in a complex with domain V of beta 2GPI (beta 2GPI-DV) revealed two possible modes of interaction of a ligand-binding module from lipoprotein receptors with beta 2GPI-DV. In both orientations, the ligand-binding module interferes with binding of beta 2GPI to anionic phospholipids; however, it interacts with two different but overlapping sets of lysine residues in beta 2GPI-DV, depending on the orientation.
Identification of Novel Liver-Specific mRNAs in Plasma for Biomarkers of Drug-Induced Liver Injury and Quantitative Evaluation in Rats Treated With Various Hepatotoxic Compounds
TOXICOLOGICAL SCIENCES
Authors: Okubo, Shingo; Miyamoto, Makoto; Takami, Kenji; Kanki, Masayuki; Ono, Atsushi; Nakatsu, Noriyuki; Yamada, Hiroshi; Ohno, Yasuo; Urushidani, Tetsuro
Abstract
Editor's Highlight: Current blood biomarkers lack sensitivity, are detectable only late after injury occurs, and lack predictive power. The present study identified novel circulating liver-specific mRNAs in plasma from rats treated with various hepatotoxicants to validate circulating liver-specific mRNAs as biomarkers for drug- induced liver injury. Liver-specific mRNAs (Alb, Ambp, Apoh, and Gc) were quantified by real-time RT-PCR in plasma from rats with single dosing of seven hepatotoxicants. Time course analysis within 24 h after dosing revealed the plasma levels of Alb and Gc mRNAs increased substantially earlier than the widely used biomarker alanine aminotransferase, suggesting that patterns of changes in circulating liver-specific mRNAs indicate the progression of liver injury. These results strongly support the reliability and usefulness of the four circulating liver-specific mRNAs as biomarkers for drug-induced liver injury.Circulating liver-specific mRNAs such as albumin (Alb) and -1-microglobulin/bikunin precursor (Ambp) have been reported to be potential biomarkers for drug-induced liver injury (DILI). We identified novel circulating liver-specific mRNAs and quantified them, together with the two previously reported mRNAs, in plasma from rats treated with various hepatotoxicants to validate circulating liver-specific mRNAs as biomarkers for DILI. Among six genes selected from the database, high liver specificity of apolipoprotein h (Apoh) and group-specific component (Gc) mRNAs were confirmed by reverse transcription (RT)-PCR and the copy numbers of these mRNAs elevated in plasma from rats treated with thioacetamide. Liver-specific mRNAs (Alb, Ambp, Apoh, and Gc) were quantified by real-time RT-PCR in plasma from rats with single dosing of seven hepatotoxicants. There were noticeable interindividual and intercompound variabilities in the severity of liver injury. The levels of four mRNAs increased almost in parallel and correlated with changes in the alanine aminotransferase (ALT) values and the hepatocellular necrosis scores at 24h after dosing. It was noteworthy that the magnitude of the increases in mRNA levels was greater than that in the ALT value. Time course analysis within 24h after dosing revealed that the timing of the increase was different among mRNA species, and the plasma levels of Alb and Gc mRNAs increased substantially earlier than the ALT values, suggesting that patterns of changes in circulating liver-specific mRNAs indicate the progression of liver injury. These results strongly support the reliability and usefulness of the four circulating liver-specific mRNAs as biomarkers for DILI.